

REF: MDOL/CS-SE/2021- 22/018

August 11, 2021

To,

Listing Department
BSE Limited
1st Floor, New Trade Wing,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400 001.
Scrip Code: 532637

Listing Department
National Stock Exchange of India Limited
"Exchange Plaza", 5th Floor,
Plot No. C-1, Block G,
Bandra - Kurla Complex,
Bandra(E), Mumbai - 400 051.
Symbol: MANGALAM

Subject: Intimation pursuant to Regulation 30 read with Schedule III of SEBI
(Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir / Madam,

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to inform you that the Company has entered into a Technology Transfer Agreement with a USD 70 Million leading pharmaceutical company/group in Nigeria, Africa region, for providing them in-house developed technology.

The salient features of the said technology transfer agreement include the following:

1. The Company will provide an in-house developed technology for manufacturing certain Anti-Malaria Active Pharmaceutical Ingredients (APIs) on limited, non-transferable and exclusive license basis for certain agreed territory;
2. The Company will also provide consultation and relevant designs for setting up an API manufacturing facility for manufacturing of the said APIs, for which the Company is one of the leading manufacturers. It is expected to be a world class API facility and one of its kind in Africa region;
3. The said manufacturing facility is expected to become operational in coming 15 to 18 months; and

Mangalam Drugs and Organics Ltd.



Regd. Office : Rupam Building, 3rd Floor, 239 P. D'Mello Road, Near G. P. O. Mumbai - 400 001.

☎ 91-22-22616200 / 6300 / 8787 ☎ 91-22-22619090 • CIN : L24230MH1972PLC116413

4. Apart from the agreed fixed consideration for the technology transfer, the Company would also be entitled to receive a 2% royalty on sales for the next 20 years.

The Company has received an advance/token payment of USD 500,000 towards the agreed fixed consideration, which is reflected as an advance in the books of accounts of the Company for the quarter ending June 30, 2021.

We request you to take the same on your records.

Thanking You,

Yours faithfully,

For Mangalam Drugs & Organics Limited



Geeta Karira

Company Secretary & Compliance Officer